Patients with schizophrenia discharged on an LAI antipsychotic had significantly lower 30-day psychiatric readmission rates than those sent home with an oral antipsychotic.
Iloperidone, an atypical antipsychotic approved for schizophrenia, appears to be safe and effective in the treatment of bipolar mania, phase 3 results of an RCT showed.
The investigational antipsychotic KarXT is effective in reducing positive and negative symptoms of schizophrenia, with a favorable side-effect profile in the pivotal EMERGENT-2 trial.
Patients with refractory schizophrenia in long-term forensic facilities show significant stabilization after reduced doses of long-acting injectable antipsychotics, new research suggests.